Stifel downgraded Cerevel Therapeutics (CERE) to Hold from Buy with a price target of $43, up from $42, after AbbVie (ABBV) said it will acquire all outstanding shares of Cerevel for $45 per share in cash.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- The biopharma stocks to own in 2024, according to Morgan Stanley
- Cerevel Therapeutics to host conference call
- Cerevel Therapeutics just downgraded at TD Cowen, here’s why
- Cerevel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next